$INSY Is Being Investigated for Potential Breaches Of Fiduciary Duty

After the close of the market on April 24, 2015 the Southern Investigating Report Foundation (“SIRF”) published an article reporting on patients who either died or suffered adverse events while being treated with Subsys, and detailed how Insys aggressively marketed Subsys. On this news, the price of Insys’s shares declined $6.00 per share, or nearly 10%, to close at $56.42 per share on April 27, 2015.

Further, on January 25, 2016, SIRF published an article alleging that Insys’s executives have continued to pressure Company employees to develop new schemes to promote the illegal and improper off-label marketing and sale of Subsys. On this news, the price of the Company’s shares declined an additional $1.07 per share, or nearly 5%, to close at $21.58 per share on January 25, 2016.

If you are a shareholder of Insys Therapeutics and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at:

You may also contact Robert H. Lefkowitz, Esq. either via email at rl@pjlfirm.com or by telephone at 212-725-1000.  One of our attorneys will personally speak with you about the case at no cost or obligation.

Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https://pjlfirm.com.   Attorney advertising. Prior results do not guarantee a similar outcome.

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/purcell-julie–lefkowitz-llp-is-investigating-insys-therapeutics-inc-for-potential-breaches-of-fiduciary-duty-by-its-board-of-directors-300319892.html